Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640138 | 0.88 | CYP4F2 (0.40) | HTTPTGS2PDE4BKDM4EGAA | |
| SCHEMBL1974691 | 0.80 | HTT (0.45) | HTTKDM4EGAAMAPTTP53 | |
| SCHEMBL19640156 | 0.79 | FNTA (0.39) | HTTPTGS2PDE4BKDM4EGAA | |
| SCHEMBL19640078 | 0.78 | CFD (0.44) | PTGS2PDE4BKDM4EGAAALDH1A1 | |
| SCHEMBL29545113 | 0.76 | SMN1; SMN2 (0.38) | HTTGAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL21994124 | 0.74 | ALOX5 (0.38) | HTTKDM4EGAAMAPTTP53 | |
| SCHEMBL21554146 | 0.74 | CYP4F2 (0.38) | HTTKDM4EGAAMAPTTP53 | |
| SCHEMBL21994125 | 0.73 | ALOX5 (0.37) | HTTPTGS2KDM4EGAAMAPT | |
| SCHEMBL7658347 | 0.73 | TOP1 (0.47) | HTTKDM4EGAAMAPTHSD17B10 | |
| SCHEMBL20262942 | 0.72 | HTT (0.41) | HTTPTGS2KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415353-B | Pegylated carfilzomib compounds | 美国安进公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3464277-B1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3464277-B1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11077198-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | AMGEN INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-10675353-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2017205392-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, FCGRT, MAN2B1 | HTT 3615/4885PTGS2 2938/4885PDE4B 4146/4885 |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | FCGRT, EPOR, MCL1 | HTT 4085/4885PTGS2 3063/4885PDE4B 4153/4885 |
| US-11077198-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | HTT 4085/4885PTGS2 3063/4885PDE4B 4153/4885 |
| US-10675353-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | HTT 4085/4885PTGS2 3063/4885PDE4B 4153/4885 |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | FCGRT, EPOR, MCL1 | HTT 4085/4885PTGS2 3063/4885PDE4B 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.